Drug intelligence / Profile preview

GF2

Development stage: Preclinical
Modality: Small Molecules, Nanoparticles → Drug Delivery Systems

Overview

GF2 is a water-soluble glycofullerene, a type of carbon nanomaterial, synthesized via a two-step modified Bingel-Hirsch methodology. It functions as a non-receptor Src kinase inhibitor, demonstrating inhibitory activity against Fyn A and BTK proteins in the low micromolar range. Studies have shown that GF2 exhibits no cytotoxicity in PANC-1 and AsPC-1 pancreatic cancer cell lines and influences cellular redox imbalance and protein levels, suggesting its potential as a nanotherapeutic for pancreatic cancer.

Targets

BTK (Bruton tyrosine kinase)FYN (Proto-oncogene tyrosine-protein kinase Fyn)

Beyond the preview

Go deeper on GF2.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GF2.

Explore the full profile